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Renal cell carcinoma (RCC) are supposed to be immuno-
genic and several clinical trials of immunotherapy using
tumor-lysate pulsed dendritic cells have been performed.
We here report on the generation and therapeutic efficacy
of RAGE-1 and MAGE-9 peptide specific cytotoxic T cell
clones.
RAGE-1 and MAGE-9 are expressed on 61% and 40% of
RCC. Six MAGE-9 and 14 RAGE-1 derived peptides were
found to be immunogenic in the context of the HLA-A2.1
MHC complex. CTL were generated by co-culture with
peptide pulsed dendritic cells (DC) or peptide pulsed
CD40-activated B cells. The latter are as efficient in anti-
gen presentation as DC, but have the advantage of being
easier to generate in great quantitities and to display func-
tional activity for a prolonged period of time. Therefore,
they are well suited for the generation of CTL clones to be
used in adoptive transfer. Three MAGE-9 and RAGE-1 spe-
cific CTL clones were generated. The clones were strictly
peptide-specific and displayed high cytotoxic activity not
only against peptide-loaded T2 cells, but also against
HLA-A2.1-positive RCC lines that naturally expressed
MAGE-9, RAGE-1 or both. The in vivo efficacy of these
MAGE-9 and RAGE-1 peptide specific CTL clones is cur-
rently being evaluated in human RCC-bearing SCID,
which received after intraperitoneal RCC injection
repeated applications of the CTL clones at weekly inter-
vals. So far, the majority of control mice became mori-
bund, but only one mouse receiving a MAGE-9 and a
RAGE-1 specific CTL developed a tumor, that had retained
MHC class I as well as MAGE-9 and RAGE-1 expression.
CTL recovered from these mice at 2 and 3 weeks after the
last T cell transfer revealed that CTL had retained their spe-
cificity and cytotoxic activity was only slightly reduced.
Thus, B cells appear well suited as antigen presenting cells
for the generation of large quantities tumor peptide spe-
cific CTL as required for adoptive transfer and cancer testis
antigens may well provide suitable target for immuno-
therapy of RCC.
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